BBIO Research and Charts

BBIO - BridgeBio Pharma Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2025-07-29 (Delayed quote data 2025-07-11)

Last 46.47	Change ⇑ +0.20 (+0.43%)	Volume 2,163,710
	Open 45.98	High 46.76	Low 45.73

8EMA (Daily) 44.87	40EMA (Daily) 40.63	50EMA (Daily) 39.80	STO (Daily) 81.221	MACD Hist (Daily) 0.278
8EMA (Weekly) 41.607	40EMA (Weekly) 34.58	50EMA (Weekly) 33.55	STO (Weekly) 95.846	MACD Hist (Weekly) 2.066


Company Profile
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.